Key Facts and Data Points

  • Scheme Name: Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP)
  • Launch Year: Originally launched in 2008 as Jan Aushadhi Scheme; re‑branded in 2016.
  • Administered By: Department of Pharmaceuticals, Ministry of Chemicals & Fertilisers.
  • Product Portfolio (2026): ~2,110 generic medicines and 315 surgical items across 29 therapeutic categories.
  • Price Advantage: Medicines priced 50‑80% lower than branded equivalents.
  • Quality Assurance: Procurement from WHO‑GMP certified manufacturers; testing in NABL‑accredited labs.
  • Sanitary Napkin Initiative: Oxo‑biodegradable pads at ₹1 per pad (since 2019).
  • Digital Tool: Jan Aushadhi Sugam App – geo‑location, price comparison, stock info.
  • Franchise Incentives: One‑time support up to ₹2 lakh for women, SC/ST, Divyangjan, ex‑servicemen entrepreneurs.
  • Current Reach (early 2026): Over 18,000 Kendras; 116 located at railway stations.
  • Target Expansion: 25,000 Kendras by March 2027, focusing on rural and underserved areas.
  • Economic Impact: Estimated ₹38,000 crore savings for citizens by June 2025.

Background and Context

The Jan Aushadhi Scheme was conceived to address the high cost of branded medicines in India, a major component of out‑of‑pocket (OOP) health spending. By promoting generic alternatives, the government aims to make essential drugs accessible to the economically weaker sections, aligning with the broader goal of Universal Health Coverage (UHC).

Significance for India / Governance / Policy

  • Financial Protection: Directly reduces OOP expenditure, a key determinant of catastrophic health spending.
  • Public‑Private Partnership Model: Franchise‑based approach encourages entrepreneurship among marginalized groups.
  • Integration with Rural Infrastructure: Leveraging Primary Agricultural Credit Societies (PACS) expands reach to remote populations.
  • Digital Governance: The Sugam App exemplifies use of technology for transparency and consumer empowerment.
  • Complementarity with Other Schemes: Works alongside Ayushman Bharat (hospitalization insurance) to cover both medicines and inpatient care.

Related Constitutional / Legal Provisions

  • Article 21 (Right to Life): Interpreted by the Supreme Court to include the right to health; affordable medicines are essential to realize this right.
  • National Health Policy 2017 & 2023: Emphasize cost‑effective generic medicines and reduction of OOP health spending.
  • Drugs and Cosmetics Act, 1940: Provides regulatory framework for generic drug approval and quality control.

References

  • Press Information Bureau (PIB) releases
  • Ministry of Chemicals & Fertilisers reports
  • National Accreditation Board for Testing and Calibration Laboratories (NABL) guidelines